2,965 results match your criteria Hepatitis D


A programme to treat chronic hepatitis B in Kiribati: progress and challenges.

Western Pac Surveill Response J 2020 Jul-Sep;11(3):21-25. Epub 2020 Sep 30.

Baylor College of Medicine, Departments of Internal Medicine, Pediatrics, Space Medicine and Global Initiatives, Houston, Texas, United States of America.

Problem: Over 290 million people worldwide suffer from chronic hepatitis B (CHB), with the highest prevalence in the Pacific islands. Mortality attributable to this disease exceeds that from HIV, tuberculosis and malaria combined in this region.

Context: CHB is a major health problem in the Pacific island nation of Kiribati. Read More

View Article and Full-Text PDF
September 2020

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.

Viruses 2021 04 12;13(4). Epub 2021 Apr 12.

Institute of Pharmacology and Toxicology, Biomedical Research Center Seltersberg (BFS), Faculty of Veterinary Medicine, Justus Liebig University Giessen, Schubertstr. 81, 35392 Giessen, Germany.

Identification of Na/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV entry inhibitors identified so far also interfere with the physiological bile acid transporter function of NTCP. The present study aimed to identify more virus-selective inhibitors of NTCP by screening of 87 propanolamine derivatives from the former development of intestinal bile acid reabsorption inhibitors (BARIs), which interact with the NTCP-homologous intestinal apical sodium-dependent bile acid transporter (ASBT). Read More

View Article and Full-Text PDF

Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac.

Vaccines (Basel) 2021 Apr 1;9(4). Epub 2021 Apr 1.

National Reference Center for Hepatitis B Viruses and Hepatitis D Viruses, Institute of Medical Virology, Justus Liebig University Giessen, 35392 Giessen, Germany.

Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn. The aim of this study was to compare the efficacy of two licensed hepatitis B vaccines, Engerix-B versus Sci-B-Vac, in preventing peripartum HBV transmission. A prospective multicenter randomized controlled study in 4 delivery centers was performed from 2009 to 2014. Read More

View Article and Full-Text PDF

Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.

PLoS One 2021 27;16(4):e0250347. Epub 2021 Apr 27.

Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Background: Hepatitis B virus (HBV) is a major global health challenge with approximately 250-350 million chronically infected individuals. An improved understanding of the demographic features and outcomes of chronic HBV infection and hepatitis D virus (HDV) infection in low-endemic areas may improve prevention, early identification and management both at individual and community levels. Here, we retrospectively analyzed the demographic and clinical characteristics, treatment rates and outcomes of adult patients with chronic HBV infection with or without HDV coinfection examined at Lausanne University Hospital, Switzerland over a 10-year period. Read More

View Article and Full-Text PDF

Current status of hepatitis delta.

Curr Opin Pharmacol 2021 Apr 22;58:62-67. Epub 2021 Apr 22.

Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece. Electronic address:

Hepatitis D virus (HDV) infection in patients chronically infected with hepatitis B virus (HBV) causes the most severe form of chronic viral hepatitis and continues to represent a major health problem. The latest data show that the global prevalence is much higher than previously considered. Therefore, screening with the detection of anti-HDV antibodies is mandatory for all chronic HBV patients. Read More

View Article and Full-Text PDF

Experimental Drugs for the Treatment of Hepatitis D.

J Exp Pharmacol 2021 16;13:461-468. Epub 2021 Apr 16.

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. Read More

View Article and Full-Text PDF

Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.

Proc Natl Acad Sci U S A 2021 Apr;118(17)

Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;

Older age at the time of infection with hepatitis viruses is associated with an increased risk of liver fibrosis progression. We hypothesized that the pace of fibrosis progression may reflect changes in gene expression within the aging liver. We compared gene expression in liver specimens from 54 adult donors without evidence of fibrosis, including 36 over 40 y old and 18 between 18 and 40 y old. Read More

View Article and Full-Text PDF

Adenosine Deaminases Acting on RNA (ADARs) and Viral Infections.

Annu Rev Virol 2021 Apr 21. Epub 2021 Apr 21.

Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, California 93106, USA; email:

C6 deamination of adenosine (A) to inosine (I) in double-stranded RNA (dsRNA) is catalyzed by a family of enzymes known as ADARs (adenosine deaminases acting on RNA) encoded by three genes in mammals. Alternative promoters and splicing produce two ADAR1 proteins, an interferon-inducible cytoplasmic p150 and a constitutively expressed p110 that like ADAR2 is a nuclear enzyme. ADAR3 lacks deaminase activity. Read More

View Article and Full-Text PDF

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan.

Sci Rep 2021 Apr 20;11(1):8554. Epub 2021 Apr 20.

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC.

The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67. Read More

View Article and Full-Text PDF

Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.

J Viral Hepat 2021 Apr 20. Epub 2021 Apr 20.

Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Hepatitis delta virus (HDV) is an obligate satellite of hepatitis B virus (HBV). HIV/HDV co-infection is associated with a high rate of hepatic decompensation events and death. We aimed to characterize the epidemiology of HDV infection in HIV/HBV co-infected individuals. Read More

View Article and Full-Text PDF

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.

Sci Rep 2021 Apr 14;11(1):8184. Epub 2021 Apr 14.

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tzyou Road, Kaohsiung, 807, Taiwan.

Hepatitis D virus (HDV) infection increases the risk of hepatocellular carcinoma (HCC) in the natural course of chronic hepatitis B (CHB) patients. Its role in patients treated with nucleotide/nucleoside analogues (NAs) is unclear. We aimed to study the role of hepatitis D in the development of HCC in CHB patients treated with NAs. Read More

View Article and Full-Text PDF

Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates.

J Hepatol 2021 Apr 9. Epub 2021 Apr 9.

Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany. Electronic address:

Background & Aims: Chronic hepatitis D virus (HDV) infections cause the most severe form of viral hepatitis. HDV requires hepatitis B virus (HBV) envelope proteins for hepatocyte entry, particle assembly and release. Eight HDV and eight HBV genotypes are presently distinguished. Read More

View Article and Full-Text PDF

Hepatitis D virus and liver transplantation: Indications and outcomes.

World J Hepatol 2021 Mar;13(3):291-299

Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MA 21205, United States.

Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Read More

View Article and Full-Text PDF

Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand?

Viruses 2021 03 26;13(4). Epub 2021 Mar 26.

Department of Tropical and Infectious Diseases, Policlinico Umberto I, University of Rome, 00161 Rome, Italy.

The discovery of the Australia Antigen in the mid-1960s led, in a few years, to the identification of the virus of Hepatitis B [... Read More

View Article and Full-Text PDF

A hepatitis B virus causes chronic infections in equids worldwide.

Proc Natl Acad Sci U S A 2021 Mar;118(13)

Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany;

Preclinical testing of novel therapeutics for chronic hepatitis B (CHB) requires suitable animal models. Equids host homologs of hepatitis C virus (HCV). Because coinfections of hepatitis B virus (HBV) and HCV occur in humans, we screened 2,917 specimens from equids from five continents for HBV. Read More

View Article and Full-Text PDF

[Clinical course and outcomes of chronic viral hepatitis D in patients from Republic of Tuva as endemic region].

Vopr Virusol 2021 03 7;66(1):74-83. Epub 2021 Mar 7.

FSBSI I.I. Mechnikov Research Institute of Vaccines and Sera; FSBEI FPE Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia.

Introduction: Hepatitis D (delta, 5) is caused by an RNA virus (hepatitis D virus, HDV) from genus Deltavirus, and is the most severe and difficult to treat disease among both viral hepatitis and infectious diseases in general. The development of HDV infection in the host organism is possible only in the presence of hepatitis B virus (HBV). Coinfection with HBV and HDV is associated with a more rapid progression of chronic viral hepatitis (CVH) to liver cirrhosis (LC) and an unfavorable outcome in comparison with HBV monoinfection. Read More

View Article and Full-Text PDF

Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis.

Viruses 2021 02 22;13(2). Epub 2021 Feb 22.

Institute of Tropical Medicine, University of Tübingen, 72076 Tübingen, Germany.

Hepatitis delta virus (HDV) coinfection will additionally aggravate the hepatitis B virus (HBV) burden in the coming decades, with an increase in HBV-related liver diseases. Between 2018 and 2019, a total of 205 HBV patients clinically characterized as chronic hepatitis B (CHB; = 115), liver cirrhosis (LC; = 21), and hepatocellular carcinoma (HCC; = 69) were recruited. HBV surface antigen (HBsAg), antibodies against surface antigens (anti-HBs), and core antigens (anti-HBc) were determined by ELISA. Read More

View Article and Full-Text PDF
February 2021

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges.

Life (Basel) 2021 Feb 22;11(2). Epub 2021 Feb 22.

Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.

Several investigations have been published on Hepatitis Delta Virus (HDV) infection in recent years, from which we have drawn the salient data to provide readers with useful information to improve their knowledge on the subject. HDV genotypes 5-8 have been recently imported to Western countries from central Africa, whose clinical relevance deserves further investigation. Ongoing HDV replication has been identified as an independent predictor of progression to cirrhosis and HCC for patients with HDV chronic hepatitis (HDV-CH). Read More

View Article and Full-Text PDF
February 2021

The year's new drugs and biologics 2020.

Drugs Today (Barc) 2021 Feb;57(2):101-177

Clarivate, Barcelona, Spain.

2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all therapeutic areas, as seen by the number of products in this year's review: approximately 50% more than the previous year. Read More

View Article and Full-Text PDF
February 2021

Molecular Phylogenetics of Hepatitis D Virus in New Zealand and the Implications for Pacific Island Countries.

Intervirology 2021 1;64(2):102-107. Epub 2021 Mar 1.

Research and Molecular Development and WHO Regional Reference Laboratory for Hepatitis B/D, Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Hepatitis delta virus (HDV) is considered a satellite virus that requires hepatitis B virus surface antigen for infectivity. HDV is endemic in some Pacific Island (PI) countries, including Kiribati and Nauru, with a unique genotype 1, "Pacific clade." The aims of this study were to determine the HDV genotypes in New Zealand and investigate the link of strains to other PI countries and the rest of the world through phylogenetics. Read More

View Article and Full-Text PDF

Clinical effects of NTCP-inhibitor myrcludex B.

J Viral Hepat 2021 Feb 17. Epub 2021 Feb 17.

School of Pharmacy, Guilin Medical University, Guilin, Guangxi, China.

With extensive research on the pathogenesis and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, the current treatment of interferon and nucleoside or nucleotide analogues provides reasonable control of viral replication in chronic hepatitis B (CHB). However, drug resistance may occur as a result of long-term treatment, and continuous covalently closed circular DNA (cccDNA) can cause disease relapse after drug withdrawal. Therefore, there is an urgent need for safe and effective antiviral drugs or methods to treat HBV and HDV infections. Read More

View Article and Full-Text PDF
February 2021

Lonafarnib: First Approval.

Authors:
Sohita Dhillon

Drugs 2021 Feb;81(2):283-289

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies. The drug was originally discovered by Merck & Co as an investigational drug in oncology. Read More

View Article and Full-Text PDF
February 2021

Hepatitis D virus antibodies and liver function profile among patients with chronic hepatitis B infection in Abuja, Nigeria.

J Infect Dev Ctries 2021 Jan 31;15(1):141-146. Epub 2021 Jan 31.

Department of Microbiology, University of Abuja Teaching Hospital, Abuja, Nigeria.

Introduction: Hepatitis D virus (HDV) is a satellite virus of hepatitis B virus (HBV). An estimated 5% of HBV infected individuals worldwide have HDV infection. There is paucity of studies in Nigeria on the burden of HDV infection. Read More

View Article and Full-Text PDF
January 2021

Microarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma.

Biomed Res Int 2021 30;2021:1093702. Epub 2021 Jan 30.

Peking University 302 Clinical Medical School, Beijing 100039, China.

Several studies have demonstrated that chronic hepatitis delta virus (HDV) infection is associated with a worsening of hepatitis B virus (HBV) infection and increased risk of hepatocellular carcinoma (HCC). However, there is limited data on the role of HDV in the oncogenesis of HCC. This study is aimed at assessing the potential mechanisms of HDV-associated hepatocarcinogenesis, especially to screen and identify key genes and pathways possibly involved in the pathogenesis of HCC. Read More

View Article and Full-Text PDF
January 2021

HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study.

Int J Drug Policy 2021 Jan 28;92:103134. Epub 2021 Jan 28.

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Electronic address:

Background: The burden of hepatitis C virus (HCV) infection among people who use drugs (PWUDs) is considerable. We aimed to screen for HCV infection using the fingerstick dried blood spot (DBS) test and to describe the cascade of hepatitis C care among PWUDs in Madrid, Spain. We also evaluated the prevalence of hepatitis B virus (HBV) and hepatitis D virus (HDV) in this population. Read More

View Article and Full-Text PDF
January 2021

The changing context of hepatitis D.

J Hepatol 2021 May 20;74(5):1200-1211. Epub 2021 Jan 20.

Division of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland; Division of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland.

The global epidemiology of hepatitis D is changing with the widespread implementation of vaccination against hepatitis B. In high-income countries that achieved optimal control of HBV, the epidemiology of hepatitis D is dual, consisting of an ageing cohort of domestic patients with advanced liver fibrosis who represent the end stage of the natural history of HDV, and of a younger generation of immigrants from endemic countries who account for the majority of new infections. As observed in Europe in the 1980s, the distinctive clinical characteristic of chronic hepatitis D in endemic countries is the accelerated progression to cirrhosis and hepatocellular carcinoma. Read More

View Article and Full-Text PDF

[Viral hepatitis A-E].

Internist (Berl) 2021 Feb;62(2):163-174

Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.

Hepatitis viruses A-E cause acute and chronic liver inflammation and thus lead to significant morbidity and mortality worldwide. They differ significantly in their biology, course of disease and therapy options. While hepatitis A virus only causes acute infection, hepatitis B can become chronic, even reactivate or occur as coinfection with hepatitis D virus. Read More

View Article and Full-Text PDF
February 2021

Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue.

J Med Chem 2021 01 28;64(1):543-565. Epub 2020 Dec 28.

National Institute of Biological Sciences, Beijing 102206, China.

Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of protects HDV-susceptible mouse model from HDV infection. Read More

View Article and Full-Text PDF
January 2021

'Double-hit' pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection.

Oxf Med Case Reports 2020 Oct 23;2020(10):omaa084. Epub 2020 Oct 23.

Hepatology Department, Luton and Dunstable University Hospital, Luton, UK.

Hepatitis delta (HDV) infection is either acquired simultaneously with, or as a superinfection to, existing Hepatitis B (HBV). It leads to a serious form of chronic viral hepatitis and accelerated liver-related morbidity and mortality including hepatocellular carcinoma. Current treatment regimes propose Pegylated interferon-alpha for 48 weeks however sustained virological response (SVR) rates remain low. Read More

View Article and Full-Text PDF
October 2020